OSR Holdings shares rise 11.62% premarket after subsidiary secures VXM01 global license with $30M upfront and $815M milestones.

OSR Holdings surged 11.62% in premarket trading following the announcement that its subsidiary, Vaximm, secured a binding term sheet for a global exclusive license of VXM01 with BCM Europe. The deal includes a $20 million upfront payment (50% cash, 50% digital assets) and potential cumulative milestone payments of up to $815 million tied to clinical and development milestones. This strategic licensing agreement, subject to board approval and due diligence, highlights VXM01’s commercial potential as an oral cancer immunotherapy, directly driving investor optimism and the sharp premarket gain.